ALLIANCES (Tables)

12 Months Ended

Dec. 31, 2019

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]

Selected financial information pertaining to alliances was as follows, including net product sales when BMS is the principal in the third-party customer sale for products subject to the alliance. Expenses summarized below do not include all amounts attributed to the activities for the products in the alliance, but only the payments between the alliance partners or the related amortization if the payments were deferred or capitalized.

	Year Ended December 31,
Dollars in Millions	2019			2018			2017
Revenues from alliances:
Net product sales	$	9,944		$	8,359		$	6,917
Alliance revenues	597			647			962
Total Revenues	$	10,541		$	9,006		$	7,879
Payments to/(from) alliance partners:
Cost of products sold	$	4,169		$	3,439		$	2,718
Marketing, selling and administrative	(127		)	(104		)	(62		)
Research and development	42			1,044			(28		)
Other (income)/expense, net	(60		)	(67		)	(46		)

Selected Alliance Balance Sheet Information:	December 31,
Dollars in Millions	2019		2018
Receivables – from alliance partners	$	347	$	395
Accounts payable – to alliance partners	1,026		904
Deferred income from alliances(a)	431		491

(a)

Includes unamortized upfront and milestone payments.

Collaborative Arrangement [Member] | Pfizer [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]

Summarized financial information related to this alliance was as follows:

	Year Ended December 31,
Dollars in Millions	2019			2018			2017
Revenues from Pfizer alliance:
Net product sales	$	7,711		$	6,329		$	4,808
Alliance revenues	218			109			64
Total Revenues	$	7,929		$	6,438		$	4,872
Payments to/(from) Pfizer:
Cost of products sold – Profit sharing	$	3,745		$	3,078		$	2,314
Other (income)/expense, net – Amortization of deferred income	(55		)	(55		)	(55		)

Selected Alliance Balance Sheet Information:	December 31,
Dollars in Millions	2019		2018
Receivables	$	247	$	220
Accounts payable	922		786
Deferred income	355		410

Collaborative Arrangement [Member] | Otsuka [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]

Summarized financial information related to this alliance was as follows:

	Year Ended December 31,
Dollars in Millions	2019		2018		2017
Revenues from Otsuka alliances:
Net product sales – Oncology territory	$	1,794	$	1,705	$	1,699
Payments to Otsuka:
Cost of products sold – Oncology fee	302		297		299

Collaborative Arrangement [Member] | Ono [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]

Summarized financial information related to this alliance was as follows:

	Year Ended December 31,
Dollars in Millions	2019		2018		2017
Revenues from Ono alliances:
Net product sales	$	194	$	165	$	145
Alliance revenues	305		294		268
Total Revenues	$	499	$	459	$	413